Home » Stocks » Can-Fite BioPharma

Can-Fite BioPharma Ltd. (CANF)

Stock Price: $2.26 USD 0.07 (3.24%)
Updated Aug 14, 2020 1:05 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 34.82M
Revenue (ttm) 596,580
Net Income (ttm) -2.81M
Shares Out 15.41M
EPS (ttm) -3.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $2.26
Previous Close $2.19
Change ($) 0.07
Change (%) 3.24%
Day's Open 2.23
Day's Range 2.19 - 2.30
Day's Volume 323,707
52-Week Range 1.08 - 4.95

More Stats

Market Cap 34.82M
Enterprise Value 34.02M
Earnings Date (est) Aug 28, 2020
Ex-Dividend Date n/a
Shares Outstanding 15.41M
Float 7.82M
EPS (basic) n/a
EPS (diluted) -3.06
FCF / Share -2.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 119,521
Short Ratio 0.21
Short % of Float n/a
Beta 1.11
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 58.36
PB Ratio 38.67
Revenue 596,580
Operating Income -3.52M
Net Income -2.81M
Free Cash Flow -3.17M
Net Cash 799,159
Net Cash / Share 0.05
Gross Margin 100.00%
Operating Margin -590.70%
Profit Margin -471.80%
FCF Margin -531.64%
ROA -105.04%
ROE -291.00%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$6.00*
(165.37% upside)
Low
5.00
Current: $2.26
High
7.00
Target: 6.00
*Average 12-month USD price target from 2 stock analysts.

Financial Performance

Financial numbers in millions ILS.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.033.820.790.170.64---1.792.64
Revenue Growth-46.81%384.16%378.18%-74.34%-----32.49%-
Gross Profit2.033.820.790.170.64---1.792.64
Operating Income-12.00-5.41-7.19-8.68-25.04-27.77-31.31-22.43-6.62-13.35
Net Income-9.59-6.57-6.43-8.39-19.77-24.52-30.81-21.93-28.37-
Shares Outstanding2.692.221.851.841.421.051.05---
Earnings Per Share-0.22-0.34-0.38-9.00-24.30-40.50-63.60-62.40-81.60-45.00
Operating Cash Flow-10.80-4.16-8.97-8.71-18.16-28.53-30.06-16.24-20.92-12.97
Capital Expenditures--0.03-0.01-0.01-0.17-0.04-0.040.080.08-0.11
Free Cash Flow-10.80-4.19-8.98-8.72-18.33-28.57-30.09-16.17-20.84-13.07
Cash & Equivalents2.763.893.5131.2066.0336.0920.774.2814.620.00
Total Debt0.04---------
Net Cash / Debt2.723.893.5131.2066.0336.0920.774.2814.620.00
Assets8.187.957.6139.1168.7139.6723.116.1118.66-
Liabilities7.304.942.6024.2127.9412.977.588.756.13-
Book Value0.883.025.0114.8740.2725.2413.23-2.6510.31-
Numbers in millions ILS, except per-share numbers.

Company Profile

Company Details

Full Name Can-Fite BioPharma Ltd.
Country Israel
Employees 8
CEO Pnina Fishman

Stock Information

Ticker Symbol CANF
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: CANF

Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.